Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Checkpoint Therapeutics, Inc. | tv487632_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Checkpoint Therapeutics, Inc. | tv487632_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Checkpoint Therapeutics, Inc. | tv487632_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Checkpoint Therapeutics, Inc. | tv487632_ex31-1.htm |
| EX-23.2 - EXHIBIT 23.2 - Checkpoint Therapeutics, Inc. | tv487632_ex23-2.htm |
| EX-10.21.1 - EXHIBIT 10.21.1 - Checkpoint Therapeutics, Inc. | tv487632ex10-21_1.htm |
| EX-10.16.1 - EXHIBIT 10.16.1 - Checkpoint Therapeutics, Inc. | tv487632ex10-16_1.htm |
| 10-K - FORM 10-K - Checkpoint Therapeutics, Inc. | tv487632_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Checkpoint Therapeutics, Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statements on Form S3 (No. 333-221493) and Form S8 (No. 333-216856 and 333-221488) of Checkpoint Therapeutics, Inc. of our report dated March 16, 2018, relating to the financial statements, which appears in this Form 10-K.
/s/ BDO USA, LLP
New York, New York
March 16, 2018